Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1Risankizumab
(D11052)		1件: Risankizumab1件: Risankizumab (D11052) 💬1件: IL23A 💬9件: C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬4件: 37, 96, 97, 271 💬
2Risankizumab (Genetical Recombination)
(D11052)		1件: Risankizumab1件: Risankizumab (D11052) 💬1件: IL23A 💬9件: C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬1件: 97 💬
3Risankizumab 10 mg/ml
(D11052)		1件: Risankizumab1件: Risankizumab (D11052) 💬1件: IL23A 💬9件: C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬1件: 96 💬
4Risankizumab 180 mg SC
(D11052)		1件: Risankizumab1件: Risankizumab (D11052) 💬1件: IL23A 💬9件: C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬1件: 96 💬
5Risankizumab 600 mg IV
(D11052)		1件: Risankizumab1件: Risankizumab (D11052) 💬1件: IL23A 💬9件: C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬1件: 96 💬
6Risankizumab 90 mg/ml
(D11052)		1件: Risankizumab1件: Risankizumab (D11052) 💬1件: IL23A 💬9件: C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬1件: 96 💬
7Risankizumab IV
(D11052)		1件: Risankizumab1件: Risankizumab (D11052) 💬1件: IL23A 💬9件: C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬2件: 96, 97 💬
8Risankizumab On-Body Injector (OBI)
(D11052)		1件: Risankizumab1件: Risankizumab (D11052) 💬1件: IL23A 💬9件: C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬1件: 96 💬
9Risankizumab SC
(D11052)		1件: Risankizumab1件: Risankizumab (D11052) 💬1件: IL23A 💬9件: C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬2件: 96, 97 💬